share_log

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $87

Benzinga ·  00:25  · Ratings

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $82 to $87.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment